Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

BACKGROUND While most children who contract COVID-19 experience mild disease, high-risk children with underlying conditions may develop severe disease, requiring interventions. Kinetics of antibodies transferred via COVID-19 convalescent plasma early in disease have not been characterized.METHODS In...

Full description

Bibliographic Details
Main Authors: Oren Gordon, Mary Katherine Brosnan, Steve Yoon, Dawoon Jung, Kirsten Littlefield, Abhinaya Ganesan, Christopher A. Caputo, Maggie Li, William R. Morgenlander, Stephanie N. Henson, Alvaro A. Ordonez, Patricia De Jesus, Elizabeth W. Tucker, Nadine Peart Akindele, Zexu Ma, Jo Wilson, Camilo A. Ruiz-Bedoya, M. Elizabeth M. Younger, Evan M. Bloch, Shmuel Shoham, David Sullivan, Aaron A.R. Tobian, Kenneth R. Cooke, Ben Larman, Jogarao V.S. Gobburu, Arturo Casadevall, Andrew Pekosz, Howard M. Lederman, Sabra L. Klein, Sanjay K. Jain
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-01-01
Series:JCI Insight
Subjects:
COVID-19
Infectious disease
Online Access:https://doi.org/10.1172/jci.insight.151518

Internet

https://doi.org/10.1172/jci.insight.151518

Similar Items